雙成藥業(002693.SZ):預計上半年淨利500萬元至700萬元 同比扭虧為盈
格隆匯7月14日丨雙成藥業(002693.SZ)披露2021年半年度業績預吿,預計上半年歸屬於上市公司股東的淨利潤500萬元至700萬元,同比扭虧為盈。基本每股收益0.0123元/股至0.0173元/股。
本報吿期公司經營業績扭虧為盈,主要有兩方面原因:
(1)公司保持主營業務穩步發展同時,積極推進受託研發業務,使得營業收入、營業利潤有所增長;
(2)報吿期內,公司取得依替巴肽注射液藥品批准文號及註冊批准文件,確認產品權利轉讓收益,利潤增加。預計報吿期內非經常性損益對淨利潤的貢獻金額約為1632萬元左右,主要系按期攤銷進入損益的政府補助收入、依替巴肽注射液產品權利轉讓收益及理財收益等所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.